Can you chip in? As an independent nonprofit, the Internet Archive is fighting for universal access to quality information. We build and maintain all our own systems, but we don’t charge for access, ...

A study on visual language models explores how shared semantic frameworks improve image–text understanding across multimodal tasks. By combining feature extraction, joint embedding, and advanced ...

Background To develop and assess the usability of a smartphone-based visual acuity (VA) test with an automatic distance calibration (ADC) function, the iOS version of WHOeyes. Methods The WHOeyes was ...

Allen Institute for AI, a prominent Seattle-based nonprofit research organization working on advancing artificial intelligence models and systems, today launched a new open-source AI agent that can ...

Engineers building browser agents today face a choice between closed APIs they cannot inspect and open-weight frameworks with no trained model underneath them. Ai2 is now offering a third option. The ...

Microsoft has released Visual Studio Code 1.112, shortly after announcing a faster release cadence for the popular editor. Despite the quicker update cycle, this release introduces several notable ...

Ohio University’s Honors Tutorial College (HTC) is now accepting applications for two Faculty Fellow positions and for the Faculty Fellow for Wellness position. Applications for these positions are ...

Keep the news in the Wayback Machine. Sign Fight for the Future's letter. Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across ...

CDN for Power Pages helps significantly improve website performance by delivering web content from servers closer to your site users. By caching files and pages on strategically distributed edge ...

Combine .Net with C# and HTMX for a streamlined development process that yields a dynamic front end without writing a line of JavaScript. There are many stacks on the server side and one of the most ...

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...